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EPC-Derived Microvesicles Protect Cardiomyocytes from
Ang II-Induced Hypertrophy and Apoptosis
Shenhong Gu1,2., Wei Zhang3., Ji Chen1,4., Ruilian Ma1,3, Xiang Xiao1, Xiaotang Ma4, Zhen Yao3*",
Yanfang Chen1,4*"
1 Department of Pharmacology and Toxicology, Boonshoft School of Medicine, Wright State University, Ohio, United States of America, 2 Department of Gerontology, the
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Abstract
Cell-released microvesicles (MVs) represent a novel way of cell-to-cell communication. Previous evidence indicates that
endothelial progenitor cells (EPCs)-derived MVs can modulate endothelial cell survival and proliferation. In this study, we
evaluated whether EPC-MVs protect cardiomyocytes (CMs) against angiotensin II (Ang II)-induced hypertrophy and
apoptosis. The H9c2 CMs were exposed to Ang II in the presence or absence of EPC-MVs. Cell viability, apoptosis, surface
area and b-myosin heavy chain (b-MHC) expression were analyzed. Meanwhile, reactive oxygen species (ROS), serine/
threonine kinase (Akt), endothelial nitric oxide synthase (eNOS), and their phosphorylated proteins (p-Akt, p-eNOS) were
measured. Phosphatidylinositol-3-kinase (PI3K) and NOS inhibitors were used for pathway verification. The role of MVcarried RNAs in mediating these effects was also explored. Results showed 1) EPC-MVs were able to protect CMs against Ang
II-induced changes in cell viability, apoptosis, surface area, b-MHC expression and ROS over-production; 2) The effects were
accompanied with the up-regulation of Akt/p-Akt and its downstream eNOS/p-eNOS, and were abolished by PI3K inhibition
or partially blocked by NOS inhibition; 3) Depletion of RNAs from EPC-MVs partially or totally eliminated the effects of EPCMVs. Our data indicate that EPC-MVs protect CMs from hypertrophy and apoptosis through activating the PI3K/Akt/eNOS
pathway via the RNAs carried by EPC-MVs.
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microRNA (miRNA) to the target cells [11,12]. Cellular MVs have
been shown to reverse endothelial injury probably through their
dual effects on NO and ROS production [13,14]. It is suggested
that bone marrow (BM)-derived endothelial progenitor cells
(EPCs) could ameliorate cardiac hypertrophy [15,16]. Of notes,
emerging evidence suggest that EPC-MVs have cell protective
features. They can increase Akt/eNOS protein expression and
phosphorylation, and induce the expression of the anti-apoptotic
protein Bcl-xL in target endothelial cells (ECs) [11]. EPC-MVs are
also shown to reprogram hypoxic resident renal cells to regenerate
[17] and to activate an angiogenic process in islet endothelium
[18]. However, the effects of EPC-MVs on CM hypertrophy and
apoptosis remains unclear.
In this study, we first determined the effects of EPC-MVs on
Ang II-induced CM hypertrophy, viability and apoptosis. Then,
we explored whether the underling mechanisms are associated
with ROS production and PI3K/Akt/eNOS signaling pathway.
In addition, we examined whether the effects of EPC-MVs were
mediated by MV- carried RNAs.

Introduction
Pathological cardiac hypertrophy leads to heart failure which
remains the major cause of cardiovascular morbidity and mortality
[1]. Its pathology is characterized by cardiomyocyte (CM)
hypertrophy, apoptosis and inflammation [2,3]. It is well accepted
that reactive oxygen species (ROS) plays an important role in the
pathogenesis of cardiac hypertrophy [4]. Ang II-induced oxidative
stress and inflammation have been demonstrated to contribute to
the pathogenesis of cardiac hypertrophy [5,6]. Some signaling
cascades such as phosphatidylinositol-3-kinase (PI3K) and serine/
threonine kinase (Akt) pathways may inhibit CM hypertrophy
[7,8]. The endothelial nitric oxide synthase (eNOS)/nitric oxide
(NO) pathway, known as an important factor in regulating
vascular function and one of the down-stream of Akt signaling, has
also been shown to reduce ROS generation and exert antiapoptotic effect on CMs [9,10].
Cellular microvesicles (MVs) released from various cell types in
response to different stimuli represent a novel way of cell-to-cell
communication. Cellular MVs are functional because they transfer
or deliver proteins and gene messages such as mRNA and
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(Ambion, NY), and the RNA concentrations were tested using
quantitative assay (Thermo Scientific, Nanodrop 2000c, FL).

Materials and Methods
Ethics Statement
Adult C57BL/6J genetic background mice were used in the
present study to obtain BM-derived EPCs. The strains were
maintained in our laboratory (22uC) with a 12-hr light/dark cycle
and fed with standard chow and drinking water ad libitum. All
experimental procedures were approved by the Wright State
University Laboratory Animal Care and Use Committee and were
in accordance with the Guide for the Care and Use of Laboratory
Animals issued by the National Institutes of Health (NIH).

Concentration-response Studies of EPC-MVs on CM
Viability
To determine the effective EPC-MV dose for increasing CM
viability, CMs were treated with Ang II (1026 M) and different
doses (0, 12.5, 25 and 50 mg/ml) of EPC-MVs. After 24 h, CMs
were harvested for viability analysis. The protein concentration of
EPC-MVs was quantified by using Bradford assay (Bio-Rad,
Hercules, CA).

Culture of Myocardial H9c2 Cell Line

Experimental Groups

H9c2 is a CM cell line (American Type Culture Collection, VA)
derived from a clone of rat embryonic heart. Cells were cultured in
Dulbecco’s Modified Eagle Medium (DMEM) supplemented with
10% fetal bovine serum (FBS) containing 100 U/ml of penicillin G
and 100 mg/ml of streptomycin, in a humidified atmosphere
containing 5% CO2 at 37uC. Before experimental intervention,
confluent cultured cells were serum-starved for 12 h [9].

Based on above studies, 1026 M of Ang II and 50 mg/ml of
EPC-MVs were used in the subsequent experiments. After
reaching confluence, H9c2 CMs were randomly assigned to 4
different groups: serum-free medium (control), Ang II, Ang
II+EPC-MVs, Ang II+drEPC-MVs. After incubation for 24 h,
cells were harvested for analyses. For pathway blocking experiments, H9c2 CMs were pre-incubated with PI3K inhibitor
(LY294002, 20 mM; Cayman Chemical, MI) or NOS inhibitor
NG-nitro-arginine methyl ester (L-NAME, 100 mM; SigmaAldrich, St. Louis, MO) for 2 h [23].

Concentration-response Studies of Ang II on CMs
Ang II (Sigma-Aldrich, St. Louis, MO) induced H9c2 injury
model was produced as previously reported [19]. In brief, H9c2
CMs were seeded in 12-well plates (56104 cells/well) or 96-well
plate (56103 cells/well) during the logarithmic growth phase.
When the cells were nearly 80% confluent, cells were incubated
with different concentrations of Ang II (0, 1029, 1028, 1027 and
1026 M) for 24 h. After co-incubation, cells were collected for
analyses (cell surface areas, viabilities and apoptosis). Upon the
completion of this study, we chose 1026 M of Ang II for the
following studies.

Detection of EPC-MV Merging with H9c2 CMs
For observing whether EPC-MVs could merge with H9c2 CMs,
a lipid membrane-intercalating fluorescent dye (PKH26) was used
to label EPC-MVs before co-incubation. Briefly, 50 mg/ml EPCMVs was mixed with 2 ml of PKH26 (261026 M; Sigma-Aldrich,
St. Louis, MO) at room temperature (RT) for 5 min. The labeled
mixtures were dialyzed in 2 ml of 1% bovine serum albumin (BSA)
and ultracentrifuged at 100,000 g for 60 min at 4uC to pellet the
labeled MVs. After washed with EBM-2, the pellet was suspended
with 1 ml of culture medium and added into H9c2 cells for 24 h
incubation. The 49, 6-diamidino-2 -phenylindole (DAPI, 1 ug/ml;
Wako Pure Chemical Industries Ltd) was used for nuclear staining.
Cell images were taken using an inverted microscope (EVOS,
NY).

Culture of EPCs
The BM derived EPCs were cultured from adult (8–10 weeks of
age, weight ranges from 25 g to 32 g) C57BL/6J genetic
background mice as we previously described [20]. Mouse tibias
and femurs were taken under deep anesthesia (pentobarbital,
150 mg/kg body weight) and BM was flushed out from tibias and
femurs. BM mononuclear cells (MNCs) were isolated by using
density gradient centrifuge method. After being washed with
Phoshate-buffered saline (PBS), BM MNCs were counted and
plated (16107 cells) on a 25 cm2 flask then grown in endothelial
cell basal medium (EBM-2) supplemented with 5% FBS containing EPC growth cytokine cocktail (Lonza, Walkersville, MD). After
3 days in culture, non-adherent cells were removed by washing
with PBS. Thereafter, culture medium was changed every 2 days.

Measurement of Cell Surface Area
The surface area of CMs in different groups was measured
according to the method of Simpson [24]. In brief, cell images
were captured by a 206magnification digital inverted microscope.
Then the images of CMs were traced and the cell surface areas
were analyzed by using Image J software (NIH, MA). The surface
areas of CMs in 6 different fields were averaged. The surface area
data in each treatment group was presented as the rate of that in
control group.

Preparation of EPC-MVs and RNA-free EPC-MVs
After being cultured for 7 d, EPC cultures were washed with
PBS, and incubated with serum-free medium overnight. The
conditional medium which contained EPC secretions was collected
and centrifuged (1,000 g, 15 min) at 4uC. Then the supernatant
was ultracentrifuged (100,000 g, 60 min) at 4uC to pellet EPCMVs [20]. For preparation of RNA-free EPC-MVs, we disrupted
the EPC-MVs with ribonuclease A (RNase A) [21,22]. First, the
EPC-MVs were incubated with 0.1% Triton X-100 (TX-100) for
5 min. Then the MV fraction was added in 200 U/ml of RNase A
(Qiagen, CA) for 90 min at 37uC. After that, EPC-MVs were
ultracentrifuged (100,000 g, 60 min) at 4uC to pellet the RNA
deleted MVs (rdMVs) for the following experiments. To verify the
effect of RNase A on MVs, the total RNAs were isolated from
EPC-MVs and EPC-rdMVs using the RNA Isolation Kit
PLOS ONE | www.plosone.org

Methyl Thiazolyl Tetrazolium (MTT) Assay
The viabilities of H9c2 CMs after different treatments were
determined using the MTT Assay Kit (Invitrogen, NY) by
following the manufacture’s protocol. The CMs culture was
replaced with 100 ml of fresh culture medium. Cells in 96-well
plate were added in 10 ml of 12 mM MTT solution and incubated
at 37uC for 4 h. Then 100 ml of the sodium dodecyl sulfate (SDS)HCl solution was added to each well and incubated at 37uC for
4 h. Finally, the 96-well plate was read by a microtiterplate reader
(Packard) at 535 nm. The percentage of viability was defined as
the relative absorbance of the treated cells versus the untreated
controls [19].
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various concentrations (0, 1029, 1028, 1027 or 1026 M) of Ang II
for 24 h. As seen in Figure 1A and 1B, Ang II dose-dependently
increased cell surface area (P,0.05). The dose-dependent effects
were also obtained in decreasing cell viability (P,0.01; Figure 1C)
and in increasing cell apoptosis (P,0.05; Figure 1D). These results
indicate the success of Ang II-induced CM hypertrophy and
apoptosis model in H9c2 CMs. Based on these data, we chose
1026 M Ang II for the following experiments.

Flow Cytometry Analysis of Cell Apoptosis
The CM apoptosis was assessed by using an Apoptosis Assay Kit
(Invitrogen, NY). The H9c2 CMs were collected by using 0.25%
trypsin, and centrifuged at 200 g for 7 min. Cells were
resuspended in 100 ml annexin-binding buffer, and incubated
with 5 ml of annexin V-FITC and 1 ml of propidium iodide (PI) at
RT in the dark for 15 min. Apoptotic cells were detected by a flow
cytometer (Accuri C6 flow cytometer). The CMs stained with both
annexin V and PI were considered to be late apoptotic CMs, and
the cells stained only with annexin V were considered to be early
apoptotic CMs [19].

Effective Dose of EPC-MVs for Preventing Ang II-induced
Reduction in CM Viability
To determine the effective dose of EPC-MVs, we co-incubated
different doses (0, 12.5, 25 or 50 mg/ml) of EPC-MVs and Ang II
(1026 M) with CMs for 24 h. We found that EPC-MVs at the dose
of 50 mg/ml did not affect the survival of H9c2 cells, but
significantly alleviated Ang II-induced reduction in CM viability
(P,0.01; Figure 2). Thus, we chose 50 mg/ml EPC-MVs for the
following experiments.

Immunohistochemistry of b-myosin Heavy Chain (bMHC)
H9c2 CMs were fixed with 2% paraformaldehyde at RT for
30 min and then permeated with 0.1% TX-100 at RT for 15 min.
After being blocked with 1% BSA and 2% donkey serum for 1 h,
the cells were incubated with b-MHC antibody (1:50; Millipore,
MA) overnight at 4uC, and followed by incubation with Cy3conjugated donkey anti-mouse antibody (1:250; Jackson, PA) at
RT in the dark for 1 h. DAPI was used for nuclear stain. Images
were obtained with an inverted microscope.

EPC-MVs Merge with H9c2 CMs after Co-incubation
The PKH26 labeled EPC-MVs were co-incubated with H9c2
CMs for 24 h. The PKH26 fluorescent was able to be detected in
the cytoplasm of the H9c2 CMs, suggesting that EPC-MVs could
merge with H9c2 CMs (Figure 3A).

Intracellular ROS Detection
Intracellular ROS levels were determined by Dihydroethidium
(DHE; Sigma-Aldrich, St. Louis, MO) staining [25,26]. Cells were
incubated with the DHE working solution (2 mM) at 37uC for 2 h.
After that, the solution was replaced with fresh culture medium,
and the cells were observed under an inverted microscope. The
cells were then trypsinized and collected by centrifugation (200 g,
7 min). The percentage of DHE positive cells was measured by
using flow cytometry method.

RNase Treatment Effectively Depletes RNAs from EPCMVs
To investigate the possible role of EPC-MV carried RNAs in
MV function, we digested the total RNAs inside MVs by using
RNAse A. As expected, we found that RNase A was able to
deplete more than 80% of total RNAs in EPC-MVs (100610.1%
and 17.563.5%, P,0.01, MVs vs. rdMVs; Figure 3B).

Western Blot Analysis

EPC-MVs Decrease Ang II-induced CM Hypertrophy via
their Carried RNAs

After different treatments, proteins from H9c2 cells were
obtained with lysis buffer (Thermo Scientific, FL) containing
protease inhibitor. The proteins were subjected to electrophoresis
and transferred onto nitrocellulose membranes. The membranes
were blocked by incubating with 5% dry milk for 1 h, and then
incubated with primary antibodies: against b-MHC (1:1000;
Sigma-Aldrich, St. Louis, MO), Akt (1:500; Cell Signaling
Technology, MA), p-Akt (Thr-308, 1:500; Cell Signaling Technology, MA), eNOS (1:500; Cell Signaling Technology, MA) or peNOS (ser-1177, 1:500; Cell Signaling Technology, MA), at 4uC
overnight. b-actin (1:4000; Sigma-Aldrich, St. Louis, MO) was
used to normalize protein loading. After being washed thoroughly,
membranes were incubated with horseradish peroxidase (HRP)
conjugated IgG (1:40000; Jackson ImmunoResearch Labs, INC.
PA) for 1 h at RT. Blots were then developed with enhanced
chemiluminescence developing solutions and quantified [27].

Ang II induced CM hypertrophy is characterized by cell size
increase and activation of fetal cardiac genes such as b-MHC [28].
Here, we found that EPC-MVs decreased Ang II-induced CM
enlargement in cell surface area (1.960.4 and 2.760.2, Ang
II+MVs vs. Ang II, P,0.01; Figure 4A and 4B) and up-regulation
in b-MHC expression (P,0.01; Figure 4A and 4C). In contrast,
EPC-rdMVs totally blocked these effects (P,0.01; Figure 4).

EPC-MVs Protect CMs from Ang II-induced Decrease in
Viability Partially via their Carried RNAs which Activate
PI3K/NOS Pathway
Fig. 5 shows co-incubation of EPC-MVs prevented Ang IIinduced decrease in cell viability (81.262.6% and 52.262.1%,
Ang II+MVs vs. Ang II, P,0.01). EPC-rdMVs were less effective
on improving H9c2 cell viability compromised by Ang II
(61.363.3% and 81.262.6%, Ang II+EPC-rdMVs vs. Ang
II+EPC-MVs, P,0.01), suggesting that the RNAs carried by
EPC-MVs were partially required for the protective effect. In
addition, LY294002 could abolish and L-NAME partially blocked
the protective effect of EPC-MVs (52.863.7%, 65.764.6% and
81.262.6%, MVs+LY294002 or MVs+L-NAME vs. MVs,
P,0.01). These demonstrate the involvement of PI3K/NOS
pathway in the protective effect of EPC-MVs.

Statistical Analysis
Experimental data were expressed as the mean 6 S.E, and were
analyzed using one-way analysis of variance (ANOVA) followed by
Bonferroni’s t-test. Values of P,0.05 were considered to be
statistical significance.

Results
Effects of Ang II on H9c2 CM Cell Surface Area, Viability
and Apoptosis
To determine the effective dose of Ang II for inducing CM
hypertrophy and apoptosis, H9c2 CM cells were treated with
PLOS ONE | www.plosone.org
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Figure 1. Concentration-response study of Ang II on H9c2 hypertrophy and apoptosis. (A) Representative images of H9c2 CMs. Scale bar,
100 mm. (B) Dose- dependent effect of Ang II on H9c2 cell surface area. (C) Dose-dependent effect of Ang II on H9c2 cell viability. (D) Dose-dependent
effect of Ang II on H9c2 cell apoptosis. **P,0.01 vs. control; 1P,0.05, 11P,0.01 vs. 1029 M Ang II; +P,0.05, ++P,0.01 vs. 1028 M Ang II; n = 6/group.
doi:10.1371/journal.pone.0085396.g001

EPC-MVs Protect CMs from Ang II-induced Apoptosis via
their Carried RNAs which Activate the PI3K/NOS Pathway

EPC-MVs Inhibit Ang II-induced ROS Overproduction in
CMs via their Carried RNAs which Activate PI3K/NOS
Pathway

As shown in Figure 6, EPC-MVs significantly decreased Ang IIinduced CM apoptosis (16.161.2% and 32.864.5%, Ang II+MVs
vs. Ang II, P,0.01). This effect was significantly reduced in the
EPC-rdMV group (22.161.6% and 16.161.2%, Ang II+rdMVs
vs. Ang II+MVs, P,0.01). Furthermore, LY294002 could abolish
and L-NAME partially blocked the protective effect of EPC-MVs
(29.161.7%, 22.461.4% and 16.161.2%, MVs+LY294002 or
MVs+L-NAME vs. MVs, P,0.01).

Oxidative stress is one of the main contributing factors that
initiate hypertrophy and apoptosis in Ang II treated CMs [28]. We
examined the role of EPC-MVs on ROS overproduction in CMs
induced by Ang II. As shown in Figure 7A, Ang II induced an

Figure 3. The incorporation of EPC-MVs with H9c2 and the
RNAs depletion from EPC-MVs. (A) Representative images showing
that EPC-MVs merge with H9c2 CMs. MVs were labeled with PKH26
(red). Nucleuses were labeled with DAPI (blue). Scale bar, 100 mm. (B)
Summarized data of total RNAs in MVs and rdMVs. RNase treatment is
effective in depleting RNAs from EPC-MVs. **P,0.01, EPC-rdMVs vs.
EPC-MVs; n = 3/group. rdMVs: RNA deleted MVs.
doi:10.1371/journal.pone.0085396.g003

Figure 2. Dose-dependent effects of EPC-MVs on H9c2
viability. Summarized data on the effects of different EPC-MV doses
on cell viabilities of H9c2 treated with 0 or 1026 M Ang II. *P,0.05,
**P,0.01 vs. control; ##P,0.01 vs. Ang II, {{P,0.01 vs. Ang II +25 mg/ml
MVs; n = 6/group.
doi:10.1371/journal.pone.0085396.g002
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Figure 4. Effects of EPC-MVs on Ang II-induced CM hypertrophy and b-MHC protein expression. (A) Representative
immunohistochemistry images of b-MHC expression in H9c2 CMs in each group. H9c2 CMs were labeled with b-MHC antibody (red), and DAPI
(blue, for nucleus). Scale bar, 100 mm. (B) Summarized data of surface areas of CMs in each group. (C) Western blot bands and graphs showing the bMHC expression in H9c2 CMs in different treatment groups. The molecular weights are 223 kDa for b-MHC and 43 kDa for b-actin. *P,0.05, **P,0.01
vs. control, #P,0.05, ##P,0.01 vs. Ang II, +P,0.05, ++P,0.01 vs. Ang II+ MVs; n = 4/group. rdMVs: RNA deleted MVs.
doi:10.1371/journal.pone.0085396.g004

increase in DHE positive cells, which was suppressed by EPCMVs. The flow cytometric data also showed that EPC-MVs
significantly suppressed Ang II-induced intracellular ROS overproduction (Figure 7B). EPC-rdMVs were less effective on
reducing Ang II-induced ROS overproduction in CMs (P,0.05).

In addition, pre-incubation with LY294002 or L-NAME could
abolish or partially block the protective effect of EPC-MVs
(P,0.01; Figure 7).

EPC-MVs Activate PI3K/Akt/eNOS Signaling Pathway in
CMs
Akt phosphorylation has been demonstrated to reflect Akt
activation. EPC-MVs significantly increased the protein expression of p-Akt/Akt (P,0.01; Figure 8A) and p-eNOS/eNOS
(P,0.01; Figure 8B) in CMs. EPC-rdMVs were less effective on
up-regulating Akt, p-Akt, eNOS and p-eNOS (P,0.05 or 0.01;
Figure 8).

Discussion
In this study, we demonstrated for the first time that EPC-MVs
protect CMs from Ang II-induced hypertrophy and apoptosis. The
underlying mechanism may partially rely on the RNAs carried by
EPC-MVs which could inhibit ROS overproduction and activate
the PI3K/Akt/eNOS signaling pathway.
MVs were first described about 30 years ago and considered to
be membrane nano-fragments (0.05–1 mm) [13]. MVs are shed
from the cell surface upon activation, stress or apoptosis. It can be
derived from various cell types, such as platelets, endothelial cells,
EPCs and leukocytes, etc [29,30]. They express different cell
surface markers, which vary according to their cell origin, and the
process of MV formation. Therefore, MVs can be used as

Figure 5. Effect of EPC-MVs on cell viability of Ang II-treated
H9c2 CMs. Summarized data on H9c2 CM viability in each group.
**P,0.01 vs. control; #P,0.05, ##P,0.01 vs. Ang II; ++P,0.01 vs. Ang
II+EPC-MVs; n = 6/group. rdMVs: RNA deleted MVs.
doi:10.1371/journal.pone.0085396.g005
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Figure 6. Effect of EPC-MVs on Ang II-induced CM apoptosis. (A) Representative flow cytometric plots of H9c2 CM apoptosis in different
treatment groups. (B) Summarized data on the percentage of apoptotic H9c2 CMs in each group. **P,0.01 vs. control, #P,0.05, ##P,0.01 vs. Ang II,
++
P,0.01 vs. Ang II+MVs; n = 6/group. rdMVs: RNA deleted MVs.
doi:10.1371/journal.pone.0085396.g006

found that EPC-MVs can effectively incorporate into CMs. This
finding is in agreement with previous reports showing that the
MVs can merge with CMs or ECs [11,37]. Most of the previous
studies on EPC-MVs are focusing on angiogenesis. For examples,
EPC-MVs are able to trigger in vivo angiogenesis in a murine
model of hindlimb ischemia [11]. Incubation of EPC-MVs with
HUVECs promotes EC survival, proliferation and in vitro formation of capillary-like structures [11]. Here, we demonstrate for the
first time that EPC-MVs prevent CMs from Ang II-induced
hypertrophy and apoptosis.
The underlying mechanisms of EPC-MVs’ protective effects on
CMs might involve oxidative stress and PI3K/Akt/eNOS
signaling pathway. Firstly, ROS overproduction has been demonstrated in Ang II-treated CMs by others [36,38] and in our
present study. Meanwhile, our results reveal that the antihypertrophic and anti-apoptotic effects of EPC-MVs are correlated with the inhibition of ROS overproduction. Secondly, we found
in this study that EPC-MVs up-regulate Akt/eNOS and p-Akt/peNOS expression in CM hypertrophy model. The PI3K/Akt
signaling pathway has been shown to play a crucial role in
protecting CMs from Ang II-induced hypertrophy and apoptosis

biomarkers for disease and indicators for therapeutic efficacy.
More recently, studies showed that MVs exert effects on antiinflammatory, anticoagulant and angiogenesis [31]. Our previous
study demonstrated that circulating MVs from db/db diabetic
mice impair the EPC function in vitro and in vivo [20]. EPCs have
been shown to have beneficial effects on cardiovascular regeneration and protection [32–34]. MVs released from EPCs could
carry their parent cell biological information and thus are
functional to the target cells [13]. For examples, EPC-MVs trigger
a repair program to injured tissues such as vasculatures, kidney
and pancreatic islets [11,17,18]. Therefore, targeting the functional properties of EPC-MVs could open a novel therapeutic
approach for vascular disease. However, there is no information
regarding the effects of EPC-MVs on cardiac hypertrophy and
apoptosis.
For testing our hypothesis that EPC-MVs play a protective role
in cardiac hypertrophy and apoptosis, we produced the model of
Ang II-induced CM hypertrophy and apoptosis as previously
reported [35,36]. As we expected, Ang II dose-dependently
induced CM hypertrophy and apoptosis, suggesting a success of
model reproduce. After co-incubation of EPC-MVs with CM, we

Figure 7. Effect of EPC-MVs on intracellular ROS production of Ang II-treated H9c2 CMs. (A) Representative images of intracellular DHE
staining and flow traces in different groups. Scale bar, 200 mm. (B) Summarized data on the measurement of ROS production in H9c2 CMs in different
groups. *P,0.05, ** P,0.01 vs. control, ##P,0.01 vs. Ang II, +P,0.05, ++P,0.01 vs. Ang II+MVs; n = 6/group. rdMVs: RNA deleted MVs.
doi:10.1371/journal.pone.0085396.g007
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Figure 8. EPC-MVs up-regulate Akt/eNOS activation in Ang II-treated H9c2 CMs. Representative Western blot bands showing Akt/p-Akt
(A), and eNOS/p-eNOS (B) expression of CMs in different treatment groups. The molecular weights are 60 kDa for Akt and p-Akt, and 140 kDa for
eNOS and p-eNOS. Summarized data on Akt/p-Akt (A) and eNOS/p-eNOS (B) expression in CMs in different treatment groups. *P,0.05, **P,0.01 vs.
control, #P,0.05, ##P,0.01 vs. Ang II, +P,0.05, ++P,0.01 vs. Ang II+MVs; n = 4/group. rdMVs: RNA deleted MVs.
doi:10.1371/journal.pone.0085396.g008

[39,40]. In particular, it is indicated that EPC-MVs are involved in
the angiogenic and anti-apoptotic program by shuttling specific
RNAs associated with PI3K/Akt and eNOS pathways [11].
Supported by these previous studies, our data suggest that
activation of PI3K/Akt/eNOS pathway could be responsible for
the effects of EPC-MVs on preventing CMs from Ang II-induced
hypertrophy and apoptosis. Thirdly, activation of eNOS/NO
production scavenges superoxide anion to prevent ROS overproduction [41,42]. These studies provide mechanism explanations
for our novel findings that EPC-MVs activate eNOS and reduce
ROS production in Ang II-treated H9c2 CMs. Finally and most
importantly, we have applied the pathway inhibitors to verify the
role of PI3K/Akt/eNOS pathway in EPC-MVs’ protective effects.
We found that the pathway blockers partially (L-NAME) or totally
(LY294002) inhibit the protective effects of EPC-MVs on Ang IIinduced CM hypertrophy, apoptosis and oxidative stress. Taken
together, our results demonstrate that EPC-MVs could trigger the
PI3K/Akt/eNOS signaling cascades to reduce ROS production,
and consequently to inhibit Ang II-induced hypertrophy and
apoptosis.
MVs exert different functions depending on their composition,
such as protein, receptor, mRNA and miRNA. A recent report
suggests that RNAs in MVs have led to the genetic communication

between cells, and the mRNAs in these RNAs could be translated
into proteins after being taken up by the cells [37]. Deregibus et al
showed that EPC-MVs activate angiogenic program in ECs by a
horizontal transfer of mRNA [11]. In the present study, we
investigated the role of EPC-MVs carried RNAs in the effects of
EPC-MVs. Interestingly, our data showed that the protective
effects of EPC-MVs on CM apoptosis, cell viability and ROS
production could be partially blocked by RNA depletion.
Depletion of RNAs abolished EPC-MVs’ effects on hypertrophy
and modulating Akt/eNOS signaling pathway, suggesting that the
other mechanisms such as their carried protein components might
also be involved. Our findings suggest that the beneficial effects of
EPC-MVs are partly mediated by their carried RNAs. Nevertheless more detailed mechanisms, such as the responsive miRNAs,
mRNAs and/or proteins, await future exploration.
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